Work

Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.

Year: 2009

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v114.22.748.748

Authors: Irene M. Ghobrial, Ravi Vij, Nikhil C. Munshi, Robert L Schlossman, Jacob Laubach, Erica L. Campagnaro, Renee Leduc, Meghan Rourke, Stacey Chuma, Janet Kunsman, Akari M. Dollard, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul Richardson

Institutions: Dana-Farber Cancer Institute, Washington University in St. Louis, Harvard University, VA Boston Healthcare System, University of Michigan, Multiple Myeloma Research Foundation

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2539176972

FWCI: 1.979

Cites:

Cited by: 10

Related to: 10